EUVIMEDPoznaj EUVIMED
Mixed-Methods-StudieStudienprotokollOpen access

The BREATH-TRACHER 2 Trial: Protocol for a Retrospective Mixed Methods Study to Establish the Utility of a Wearable Device in the Detection of Chronic Obstructive Pulmonary Disease Exacerbations

Beyza Toprak iD, Louise Hamilton iD, Burcu Kolukisa Birgec iD, Alexander Balfour Mullen iD

JMIR Research Protocols · 2025

DOI: 10.2196/79503 ↗

At a glance

Mixed-Methods-Studie in JMIR Research Protocols, 2025. Written by Beyza Toprak and 3 co-authors. Institution: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, United Kingdom, 44 14154…. Major MEDLINE topics: Pulmonary Disease, Chronic Obstructive, Wearable Electronic Devices. 33 references. The full text is freely available in PubMed Central.

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

Background

Acute exacerbations of chronic obstructive pulmonary disease (eCOPD) are a major clinical challenge, often leading to frequent emergency room visits and significantly reducing patients’ quality of life. Early detection through wearable devices could facilitate timely interventions at the community level, reducing hospital admissions and disease-related morbidity and mortality.

Objective

This study seeks to retrospectively assess the feasibility and reliability of the Frontier X2 wearable device for continuous monitoring of clinically relevant physiological signals in volunteers with chronic obstructive pulmonary disease (COPD) who experience acute exacerbations. In particular, the study aims to characterize early physiological alterations that may occur prior to the exacerbation of COPD, assessing the ability of the device to capture these changes in the real-world settings.

Methods

This single-center feasibility study involves prospective physiological data collection with retrospective analytical evaluation of physiological changes occurring around clinically confirmed COPD exacerbations. A total of 30 participants with COPD (Modified Medical Research Council Grades 1‐4) who have experienced at least one exacerbation within the past 12 months will be included. Each participant will wear a continuous physiological monitoring device in their free-living environment for up to 18 months or until an eCOPD event occurs. The device will continuously collect physiological signals, including heart rate, respiratory rate, and heart rate variability. Data will be analyzed using statistical quality control methods, specifically the Cumulative Sum approach, to identify physiological deviations occurring within 7 days (168 h) prior to an exacerbation event. These findings will be correlated with clinical records and qualitative data. Qualitative information will be obtained through biweekly self-administered questionnaires assessing symptom changes and through additional adherence and usability questionnaires completed during home visits conducted every 2 weeks by the researcher.

Results

Recruitment for this study started in June 2024 and was completed in July 2025. It is anticipated that data collection will be completed within 18 months of study initiation, with data analysis finalized by December 2025. Final results will be published in January 2026.

Conclusions

The BREATH-TRACHER 2 study will evaluate the use of the Frontier X2 device in participants with COPD in home settings. The Frontier X2 device, if successful, has the potential to transform COPD management and support proactive care, leading to enhanced clinical outcomes and reduced disease mortality and morbidity.

Subjects

MeSH terms (MEDLINE)

Pulmonary Disease, Chronic ObstructiveWearable Electronic DevicesFemaleHumansMaleDisease ProgressionFeasibility StudiesMonitoring, PhysiologicQuality of LifeReproducibility of ResultsRetrospective StudiesObservational Studies as Topic

Author keywords

COPDacutechronic obstructive pulmonary diseasedigital healthexacerbationfeasibility studyhome monitoringprotocolrespirationrespiratoryvital signswearable device

Authors and institutions

  • Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, United Kingdom, 44 1415484409, 44 1415522562.
  • Vale Centre for Health and Care, Glasgow, United Kingdom.

ORCID profiles: Beyza Toprak, Louise Hamilton, Burcu Kolukisa Birgec, Alexander Balfour Mullen

Cite

APA

Toprak, B., Hamilton, L., Kolukisa Birgec, B., & Mullen, A. B. (2025). The BREATH-TRACHER 2 Trial: Protocol for a Retrospective Mixed Methods Study to Establish the Utility of a Wearable Device in the Detection of Chronic Obstructive Pulmonary Disease Exacerbations. JMIR Research Protocols. https://doi.org/10.2196/79503

Vancouver

Toprak B, Hamilton L, Kolukisa Birgec B, Mullen AB. The BREATH-TRACHER 2 Trial: Protocol for a Retrospective Mixed Methods Study to Establish the Utility of a Wearable Device in the Detection of Chronic Obstructive Pulmonary Disease Exacerbations. JMIR Research Protocols. 2025. doi:10.2196/79503

BibTeX
@article{Toprak2025,
  author = {Toprak, Beyza and Hamilton, Louise and Kolukisa Birgec, Burcu and Mullen, Alexander Balfour},
  title = {The BREATH-TRACHER 2 Trial: Protocol for a Retrospective Mixed Methods Study to Establish the Utility of a Wearable Device in the Detection of Chronic Obstructive Pulmonary Disease Exacerbations},
  journal = {JMIR Research Protocols},
  year = {2025},
  doi = {10.2196/79503}
}
Start for free →